DS-5565 Clinical Pharmacology Study An Open-Label, Single-Dose Study to Assess the Pharmacokinetics and Safety of DS-5565 in Japanese Subjects with varying degrees of renal function

Trial Profile

DS-5565 Clinical Pharmacology Study An Open-Label, Single-Dose Study to Assess the Pharmacokinetics and Safety of DS-5565 in Japanese Subjects with varying degrees of renal function

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs Mirogabalin (Primary)
  • Indications Neuropathic pain; Pain; Postherpetic neuralgia
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 30 Sep 2016 Results presented at the 16th World Congress on Pain
    • 31 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top